Rosetta Genomics Ltd
OTC:ROSGQ
Rosetta Genomics Ltd
Cost of Revenue
Rosetta Genomics Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rosetta Genomics Ltd
OTC:ROSGQ
|
Cost of Revenue
-$7.4m
|
CAGR 3-Years
-119%
|
CAGR 5-Years
-87%
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cost of Revenue
-$1.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cost of Revenue
-$87m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cost of Revenue
-$9.4m
|
CAGR 3-Years
-110%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cost of Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rosetta Genomics Ltd's Cost of Revenue?
Cost of Revenue
-7.4m
USD
Based on the financial report for Dec 31, 2016, Rosetta Genomics Ltd's Cost of Revenue amounts to -7.4m USD.
What is Rosetta Genomics Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-87%
Over the last year, the Cost of Revenue growth was -19%. The average annual Cost of Revenue growth rates for Rosetta Genomics Ltd have been -119% over the past three years , -87% over the past five years .